These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 20545593)

  • 1. The economics of improved cancer survival rates: better outcomes, higher costs.
    Uyl-de Groot CA; de Groot S; Steenhoek A
    Expert Rev Pharmacoecon Outcomes Res; 2010 Jun; 10(3):283-92. PubMed ID: 20545593
    [TBL] [Abstract][Full Text] [Related]  

  • 2. American Society of Clinical Oncology guidance statement: the cost of cancer care.
    Meropol NJ; Schrag D; Smith TJ; Mulvey TM; Langdon RM; Blum D; Ubel PA; Schnipper LE;
    J Clin Oncol; 2009 Aug; 27(23):3868-74. PubMed ID: 19581533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of screening for cancer in the Nordic countries on deaths, cost and quality of life up to the year 2017.
    Hristova L; Hakama M
    Acta Oncol; 1997; 36 Suppl 9():1-60. PubMed ID: 9143316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Taishotoyama Symposium Barriers to colorectal cancer screening: economics, capacity and adherence.
    Inadomi JM
    J Gastroenterol Hepatol; 2008 Dec; 23 Suppl 2():S198-204. PubMed ID: 19120898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer Care Ontario's New Drug Funding Program: controlled introduction of expensive anticancer drugs.
    Evans WK; Nefsky M; Pater J; Browman G; Cowan DH
    Chronic Dis Can; 2002; 23(4):152-6. PubMed ID: 12517323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of insurance with cancer care utilization and outcomes.
    Ward E; Halpern M; Schrag N; Cokkinides V; DeSantis C; Bandi P; Siegel R; Stewart A; Jemal A
    CA Cancer J Clin; 2008; 58(1):9-31. PubMed ID: 18096863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cost of cancer.
    Cromwell J; Gertman P
    Laryngoscope; 1979 Mar; 89(3):393-409. PubMed ID: 107379
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Do increases in the market share of managed care influence quality of cancer care in the fee-for-service sector?
    Keating NL; Landrum MB; Meara E; Ganz PA; Guadagnoli E
    J Natl Cancer Inst; 2005 Feb; 97(4):257-64. PubMed ID: 15713960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outpatient cancer drug costs: changes, drivers, and the future.
    Halbert RJ; Zaher C; Wade S; Malin J; Lawless GD; Dubois RW
    Cancer; 2002 Feb; 94(4):1142-50. PubMed ID: 11920485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risks of online direct-to-consumer tumor markers for cancer screening.
    Lovett KM; Liang BA; Mackey TK
    J Clin Oncol; 2012 May; 30(13):1411-4. PubMed ID: 22355060
    [No Abstract]   [Full Text] [Related]  

  • 11. Innovative cancer therapies: putting costs into context.
    Khayat D
    Cancer; 2012 May; 118(9):2367-71. PubMed ID: 21918962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Era of personalized medicine may herald end of soaring cancer costs.
    Keogh B
    J Natl Cancer Inst; 2012 Jan; 104(1):12-3, 16-7. PubMed ID: 22173586
    [No Abstract]   [Full Text] [Related]  

  • 13. [Health care expenditures linked to the use of targeted therapies and diagnostic tests for cancer patients].
    Marino P; Bertucci F; Gonçalves A; Seror V
    Med Sci (Paris); 2012 Mar; 28 Spec No 1():19-23. PubMed ID: 22494652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The cost of chemotherapy].
    Lévy C; Bonastre J
    Bull Cancer; 2003 Nov; 90(11):976-82. PubMed ID: 14706901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Valuing end-of-life care in the United States: the case of new cancer drugs.
    Sorenson C
    Health Econ Policy Law; 2012 Oct; 7(4):411-30. PubMed ID: 23079300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility.
    American Society of Clinical Oncology
    J Clin Oncol; 2003 Jun; 21(12):2397-406. PubMed ID: 12692171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Cost of medications in the oncology sector in the context of health economics].
    Walter E; Batista A
    Wien Med Wochenschr; 2008; 158(7-8):227-33. PubMed ID: 18500477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current and projected annual direct costs of screening asymptomatic men for prostate cancer using prostate-specific antigen.
    Krahn MD; Coombs A; Levy IG
    CMAJ; 1999 Jan; 160(1):49-57. PubMed ID: 9934343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Costs of cancer care: a view from the centers for Medicare and Medicaid services.
    Bach PB
    J Clin Oncol; 2007 Jan; 25(2):187-90. PubMed ID: 17210938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Cancer Advances 2005: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.
    Herbst RS; Bajorin DF; Bleiberg H; Blum D; Hao D; Johnson BE; Ozols RF; Demetri GD; Ganz PA; Kris MG; Levin B; Markman M; Raghavan D; Reaman GH; Sawaya R; Schuchter LM; Sweetenham JW; Vahdat LT; Vokes EE; Winn RJ; Mayer RJ;
    J Clin Oncol; 2006 Jan; 24(1):190-205. PubMed ID: 16326753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.